Camp4 Therapeutics said CEO Josh Mandel-Brehm will discuss the company’s planned SYNGAP1 clinical trial launch in an interview with CNBC. The move follows Austr

Camp4 Therapeutics said CEO Josh Mandel-Brehm will discuss the company’s planned SYNGAP1 clinical trial launch in an interview with CNBC. The move follows Australian clearance for a Phase 1/2 study of its disease-modifying therapy for rare haploinsufficient disorders.